A phase 2 basket trial of tarlatamab in patients with advanced DLL3-expressing tumors: University of California Lung Cancer Consortium UCCC-01/UCLA L-10. This is an ASCO Meeting Abstract from the 2025 ...

a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT. During the webcast, members of Anaptys management ...

Format – Fireside chat and one-on-one investor meetings Date and Time – Wednesday, June 11, 2025, at 8:40am ET / 5:40am PT Live webcasts of the data release, as well as the presentation ...

a depleter and agonist targeting PD-1+ T cells, for moderate-to-severe rheumatoid arthritis on Tuesday, June 3, 2025, at 4:15pm ET / 1:15pm PT. During the webcast, members of Anaptys management will ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...

NVO CEO exits amid pressure. Sanofi is set to buy VIGL. Pfizer inks $1.25B 3SBio deal. FDA okays Roche eye drug for new indication. Merck starts key cancer study.

Here's a recap of the week’s most important stories.

Chugai files regulatory application with Japanese MHLW for additional indication of Tecentriq to treat thymic carcinoma: Tokyo Tuesday, May 20, 2025, 15:00 Hrs [IST] Chugai Pharma ...

From antibody-drug conjugates to PARP inhibitors, innovative treatments are offering new hope for patients with ...